Please Wait
Applying Filters...
menu
    • menu
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-03

    Virtual Booth

    An Enquiry

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Imlunestrant

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Onco360® Named Specialty Pharmacy Partner for Inluriyo
    Onco360® Named Specialty Pharmacy Partner for Inluriyo

    06 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/06/3161616/0/en/Onco360-Has-Been-Selected-as-a-Specialty-Pharmacy-Partner-for-INLURIYO-imlunestrant.html

    GLOBENEWSWIRE
    06 Oct 2025
    Share Share
    FDA Approves Guardant360® Cdx For Eli Lilly's Inluriyo
    FDA Approves Guardant360® Cdx For Eli Lilly's Inluriyo

    29 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250929438398/en/FDA-Approves-Guardant360-CDx-as-Companion-Diagnostic-for-Eli-Lilly-and-Companys-Inluriyo-imlunestrant-for-Treatment-of-ESR1-mutated-Advanced-Breast-Cancer

    BUSINESSWIRE
    29 Sep 2025
    Share Share
    FDA Approves Inluriyo for Adults Metastatic Breast Cancer
    FDA Approves Inluriyo for Adults Metastatic Breast Cancer

    26 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/us-fda-approves-inluriyo-imlunestrant-for-adults-with-er-her2-esr1-mutated-advanced-or-metastatic-breast-cancer-302567490.html

    PR NEWSWIRE
    26 Sep 2025
    Share Share
    Eli Lilly`s Inluriyo Receives Approval in US
    Eli Lilly`s Inluriyo Receives Approval in US

    25 Sep 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218881

    FDA
    25 Sep 2025
    Share Share
    Lilly to Present Imlunestrant Results at Breast Cancer Symposium
    Lilly to Present Imlunestrant Results at Breast Cancer Symposium

    01 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lilly-to-present-results-from-phase-3-ember-3-study-of-imlunestrant-an-oral-serd-and-additional-results-from-its-breast-cancer-portfolio-at-the-san-antonio-breast-cancer-symposium-302294496.html

    PR NEWSWIRE
    01 Nov 2024
    Share Share